Dual-release hydrocortisone for treatment of adrenal insufficiency: a systematic review

  • 17 Accesses


Dual-release hydrocortisone is a new hydrocortisone formulation developed to improve the pharmacokinetic and the pharmacodynamic profiles and patient compliance. The aim of this review is to summarize the main knowledge on dual-release hydrocortisone, with particular attention to pharmacokinetics, metabolic and health-related quality-of-life aspects, bone health and drug safety.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 199

This is the net price. Taxes to be calculated in checkout.

Fig. 1


  1. 1.

    S. Bensing, A.L. Hulting, E.S. Husebye, O. Kämpe, K. Løvås, Management of endocrine disease: epidemiology, quality of life and complications of primary adrenal insufficiency: a review. Eur. J. Endocrinol. 175, R107–R116 (2016).

  2. 2.

    W. Arlt, B. Allolio, Adrenal insufficiency. Lancet 361, 1881–1893 (2003)

  3. 3.

    E.S. Husebye, B. Allolio, W. Arlt, K. Badenhoop, S. Bensing, C. Betterle, A. Falorni, E.H. Gan, A.L. Hulting, A. Kasperlik-Zaluska, O. Kämpe, K. Løvås, G. Meyer, S.H. Pearce, Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J. Intern. Med. 275, 104–115 (2014).

  4. 4.

    S.R. Bornstein, B. Allolio, W. Arlt, A. Barthel, A. Don-Wauchope, G.D. Hammer, E.S. Husebye, D.P. Merke, M.H. Murad, C.A. Stratakis, D.J. Torpy, Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 364–389 (2016).

  5. 5.

    R. Bergthorsdottir, M. Leonsson-Zachrisson, A. Odén, G. Johannsson, Premature mortality in patients with Addison’s disease: a population-based study. J. Clin. Endocrinol. Metab. 91, 4849–4853 (2006)

  6. 6.

    I.L. Ross, R. Bergthorsdottir, N.S. Levitt, D.A. Schatz, G. Johannsson, A.D. Marais, Increased cardiovascular risk in South African patients with Addison’s disease. Horm. Metab. Res. 45, 905–910 (2013).

  7. 7.

    I.L. Ross, R. Bergthorsdottir, N. Levitt, J.A. Dave, D. Schatz, D. Marais, G. Johannsson, Cardiovascular risk factors in patients with Addison’s disease: a comparative study of South African and Swedish patients. PLoS ONE 9, e90768 (2014).

  8. 8.

    H. Filipsson, J.P. Monson, M. Koltowska-Häggström, A. Mattsson, G. Johannsson, The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J. Clin. Endocrinol. Metab. 91, 3954–3961 (2006)

  9. 9.

    R. Giordano, S. Marzotti, M. Balbo, S. Romagnoli, E. Marinazzo, R. Berardelli, G. Migliaretti, A. Benso, A. Falorni, E. Ghigo, E. Arvat, Metabolic and cardiovascular profile in patients with Addison’s disease under conventional glucocorticoid replacement. J. Endocrinological Investig. 32, 917–923 (2009).

  10. 10.

    G. Johannsson, R. Bergthorsdottir, A.G. Nilsson, H. Lennernas, T. Hedner, S. Skrtic, Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur. J. Endocrinol. 161, 119–130 (2009).

  11. 11.

    R. Giordano, F. Guaraldi, R. Berardelli, I. Karamouzis, V. D’Angelo, C. Zichi, S. Grottoli, E. Ghigo, E. Arvat, Dual-release hydrocortisone in Addison’s disease - a review of the literature. Eur. Endocrinol. 10, 75–78 (2014).

  12. 12.

    G. Johannsson, A.G. Nilsson, R. Bergthorsdottir, P. Burman, P. Dahlqvist, B. Ekman, B.E. Engström, T. Olsson, O. Ragnarsson, M. Ryberg, J. Wahlberg, B.M. Biller, J.P. Monson, P.M. Stewart, H. Lennernäs, S. Skrtic, Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J. Clin. Endocrinol. Metab. 97, 473–481 (2012).

  13. 13.

    G. Johannsson, H. Lennernäs, C. Marelli, K. Rockich, S. Skrtic, Achieving a physiological cortisol profile with once-daily dual-release hydrocortisone: a pharmacokinetic study. Eur. J. Endocrinol. 175, 85–93 (2016).

  14. 14.

    F. Ceccato, E. Selmin, C. Sabbadin, M. Dalla Costa, G. Antonelli, M. Plebani, M. Barbot, C.Betterle, M. Boscaro, C. Scaroni, Improved salivary cortisol rhythm with dual-release hydrocortisone. Endocr. Connect. 7, 965–974 (2018).

  15. 15.

    M. Quinkler, R. Miodini Nilsen, K. Zopf, M. Ventz, M. Øksnes, Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur. J. Endocrinol. 172, 619–626 (2015).

  16. 16.

    R. Giordano, F. Guaraldi, E. Marinazzo, F. Fumarola, A. Rampino, R. Berardelli, I. Karamouzis, M. Lucchiari, T. Manetta, G. Mengozzi, E. Arvat, E. Ghigo, Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison’s disease. Endocrine 51, 360–368 (2016).

  17. 17.

    A.M. Isidori, M.A. Venneri, C. Graziadio, C. Simeoli, D. Fiore, V. Hasenmajer, E. Sbardella, D. Gianfrilli, C. Pozza, P. Pasqualetti, S. Morrone, A. Santoni, F. Naro, A. Colao, R. Pivonello, A. Lenzi, Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 6, 173–185 (2018).

  18. 18.

    L.M. Mongioì, R.A. Condorelli, S. La Vignera, A.E. Calogero, Dual-release hydrocortisone treatment: glycometabolic profile and health-related quality of life. Endocr. Connect. 7, 211–219 (2018).

  19. 19.

    V. Guarnotta, A. Ciresi, G. Pillitteri, C. Giordano, Improved insulin sensitivity and secretion in prediabetic patients with adrenal insufficiency on dual-release hydrocortisone treatment: a 36-month retrospective analysis. Clin. Endocrinol. (Oxf.). 88(5), 665–672 (2018).

  20. 20.

    V. Guarnotta, C. Di Stefano, A. Santoro, A. Ciresi, A. Coppola, C. Giordano, Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency. Endocr. Connect. 8(7), 853–862 (2019).

  21. 21.

    V. Guarnotta, M.I. Mineo, S. Radellini, G. Pizzolanti, C. Giordano, Dual-release hydrocortisone improves hepatic steatosis in patients with secondary adrenal insufficiency: a real-life study. Ther. Adv. Endocrinol. Metab. 10, 2042018819871169 (2019).

  22. 22.

    A. Al Nofal, I. Bancos, K. Benkhadra, N.M. Ospina, A. Javed, E. Kapoor, K. Muthusamy, J.P. Brito, A.F. Turcu, Z. Wang, L. Prokop, D.Z. Erickson, A.N. Lteif, N. Natt, M.H. Murad, Glucocorticoid replacement regimens in chronic adrenal insufficiency: a systematic review and meta-analysis. Endocr. Pract. 23, 17–31 (2017).

  23. 23.

    V.B. Boesen, T. Christoffersen, T. Watt, S.W. Borresen, M. Klose, U. Feldt-Rasmussen, PlenadrEMA: effect of dual-release versus conventional hydrocortisone on fatigue, measured by ecological momentary assessments: a study protocol for an open-label switch pilot study. BMJ Open. 8(1), e019487 (2018).

  24. 24.

    V. Camozzi, C. Betterle, A.C. Frigo, V. Zaccariotto, M. Zaninotto, E. De Caneva, P. Lucato, W. Gomiero, S. Garelli, C. Sabbadin, M. Salvà, M.D. Costa, M. Boscaro, G. Luisetto, Vertebral fractures assessed with dual-energy X-ray absorptiometry in patients with Addison’s disease on glucocorticoid and mineralocorticoid replacement therapy. Endocrine 59, 319–329 (2018).

  25. 25.

    S. Frara, S. Chiloiro, T. Porcelli, A. Giampietro, G. Mazziotti, L. De Marinis, A. Giustina, Bone safety of dual-release hydrocortisone in patients with hypopituitarism. Endocrine 60, 528–531 (2018).

  26. 26.

    D.A. Vassiliadi, S. Tsagarakis, Multiple benefits from dual release hydrocortisone: a “hard” view from bones. Endocrine 61, 177–179 (2018).

  27. 27.

    A.G. Nilsson, C. Marelli, D. Fitts, R. Bergthorsdottir, P. Burman, P. Dahlqvist, B. Ekman, B.E. Engström, T. Olsson, O. Ragnarsson, M. Ryberg, J. Wahlberg, H. Lennernäs, S. Skrtic, G. Johannsson, Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency. Eur. J. Endocrinol. 171, 369–377 (2014).

  28. 28.

    A.G. Nilsson, R. Bergthorsdottir, P. Burman, P. Dahlqvist, B. Ekman, B.E. Engström, O. Ragnarsson, S. Skrtic, J. Wahlberg, H. Achenbach, S. Uddin, C. Marelli, G. Johannsson, Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study. Eur. J. Endocrinol. 176, 715–725 (2017).

Download references


This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Author information

Correspondence to Aldo Eugenio Calogero.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mongioì, L.M., Condorelli, R.A., Barbagallo, F. et al. Dual-release hydrocortisone for treatment of adrenal insufficiency: a systematic review. Endocrine (2020) doi:10.1007/s12020-020-02187-7

Download citation


  • Adrenal insufficiency
  • Dual-release hydrocortisone
  • Pharmacokinetic
  • Metabolism